These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3010929)

  • 1. Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure.
    Ikram H; Webster MW; Nicholls MG; Lewis GR; Richards AM; Crozier IG
    Aust N Z J Med; 1986 Feb; 16(1):61-3. PubMed ID: 3010929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Captopril and spironolactone therapy for refractory congestive heart failure.
    Dahlström U; Karlsson E
    Am J Cardiol; 1993 Jan; 71(3):29A-33A. PubMed ID: 8422001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy of captopril and spironolactone for refractory congestive heart failure.
    Han YL; Tong M; Jing QM; Hu XL; Liu JQ
    Chin Med J (Engl); 1994 Sep; 107(9):688-92. PubMed ID: 7805462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor.
    van Vliet AA; Donker AJ; Nauta JJ; Verheugt FW
    Am J Cardiol; 1993 Jan; 71(3):21A-28A. PubMed ID: 8422000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure.
    Cody RJ; Covit AB; Schaer GL; Laragh JH
    J Am Coll Cardiol; 1983 Apr; 1(4):1154-9. PubMed ID: 6187789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure.
    Kambara A; Holycross BJ; Wung P; Schanbacher B; Ghosh S; McCune SA; Bauer JA; Kwiatkowski P
    J Cardiovasc Pharmacol; 2003 Jun; 41(6):830-7. PubMed ID: 12775959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES).
    Pitt D
    Eur Heart J; 1995 Dec; 16 Suppl N():107-10. PubMed ID: 8682055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.
    Zannad F
    Am J Cardiol; 1993 Jan; 71(3):34A-39A. PubMed ID: 8422003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti-aldosterone therapy in severe heart failure].
    van Guldener C; Donker AJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New drug preparations used for treating congestive heart failure: converting enzyme inhibitors, nitroprusside, nitrates and calcium channel blockers].
    Rudolf W; Froer KL; Hall D
    Ter Arkh; 1982; 54(11):110-2. PubMed ID: 6186040
    [No Abstract]   [Full Text] [Related]  

  • 13. Restoration of cardiac function and structure by converting enzyme inhibition possibilities and limitations of long-term treatment in hypertension and heart failure.
    Fouad FM; Tarazi RC
    J Cardiovasc Pharmacol; 1986; 8 Suppl 1():S53-7. PubMed ID: 2422493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acute reversible kidney insufficiency due to enalapril during diuretic-treated heart insufficiency].
    Degenhardt S
    Dtsch Med Wochenschr; 1987 Jun; 112(24):960-3. PubMed ID: 3036457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone in the management of congestive heart failure.
    Muller JE
    Am J Cardiol; 1990 Jun; 65(23):51K-53K. PubMed ID: 2353671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure.
    Franciosa JA; Wilen MM; Jordan RA
    J Am Coll Cardiol; 1985 Jan; 5(1):101-7. PubMed ID: 2981088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy.
    de Resende MM; Kriegel AJ; Greene AS
    J Cardiovasc Pharmacol; 2006 Dec; 48(6):265-73. PubMed ID: 17204904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
    Saito M; Nakayama D; Takada M; Hirooka K; Yasumura Y
    J Clin Pharm Ther; 2006 Dec; 31(6):535-40. PubMed ID: 17176359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril.
    Turini GA; Waeber B; Brunner HR
    Eur Heart J; 1983 Jan; 4 Suppl A():189-97. PubMed ID: 6301835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.